Return-Path: <p_bruneau@hotmail.com>
X-Original-To: polytech_liste-egc@sympa62.u12.univ-nantes.prive
Delivered-To: polytech_liste-egc@sympa62.u12.univ-nantes.prive
Received: from bouncesmtp2.univ-nantes.fr (BounceSMTP2.univ-nantes.prive [172.20.12.67])
	by sympa62.u12.univ-nantes.prive (Postfix) with ESMTP id 875C814006DE
	for <polytech_liste-egc@sympa62.u12.univ-nantes.prive>; Sat, 13 Feb 2021 14:27:50 +0100 (CET)
Received: from mx2.d101.univ-nantes.fr (MX2.univ-nantes.fr [193.52.101.136])
	by bouncesmtp2.univ-nantes.fr (Postfix) with ESMTP id 8088361F0E8
	for <polytech_liste-egc@sympa62.u12.univ-nantes.prive>; Sat, 13 Feb 2021 14:27:50 +0100 (CET)
Received: from localhost (localhost [127.0.0.1])
	by mx2.d101.univ-nantes.fr (Postfix) with ESMTP id 76EF8B4A252
	for <liste-egc@polytech.univ-nantes.fr>; Sat, 13 Feb 2021 14:27:50 +0100 (CET)
X-Virus-Scanned: Debian amavisd-new at univ-nantes.fr
X-Spam-Flag: NO
X-Spam-Score: 1.312
X-Spam-Level: *
X-Spam-Status: No, score=1.312 tagged_above=-1000 required=5
	tests=[CRM114_UNSURE=0.1, DKIM_SIGNED=0.1, DKIM_VALID=-0.1,
	DKIM_VALID_AU=-0.1, DKIM_VALID_EF=-0.1, FREEMAIL_FROM=0.001,
	FREEMAIL_REPLY=1, HTML_MESSAGE=0.001, MR_NOT_ATTRIBUTED_IP=0.2,
	RCVD_IN_DNSWL_NONE=-0.0001, RCVD_IN_MSPIKE_H2=-0.001,
	RCVD_IN_WSFF=0.01, SPF_HELO_NONE=0.001, SPF_PASS=-0.001,
	UN_PHISHING_COMPTE=0.1, UN_PHISHING_PW=0.1, URIBL_BLOCKED=0.001]
	autolearn=disabled
X-CRM114-Status: UNSURE ( 2.7442 )
X-CRM114-CacheID: 
Authentication-Results: univ-nantes.fr (amavisd-new); dkim=pass (2048-bit key)
	header.d=yahoo.fr
Received: from mx2.d101.univ-nantes.fr ([127.0.0.1])
	by localhost (univ-nantes.fr [127.0.0.1]) (amavisd-new, port 10024)
	with ESMTP id n9SRDdb-QGKU for <liste-egc@polytech.univ-nantes.fr>;
	Sat, 13 Feb 2021 14:27:48 +0100 (CET)
X-Greylist: domain auto-whitelisted by SQLgrey-1.6.7
Received: from sonic301-2.consmr.mail.bf2.yahoo.com (sonic301-2.consmr.mail.bf2.yahoo.com [74.6.129.41])
	by mx2.d101.univ-nantes.fr (Postfix) with ESMTPS id 303B165CF85
	for <liste-egc@polytech.univ-nantes.fr>; Sat, 13 Feb 2021 14:27:48 +0100 (CET)
DKIM-Signature: v=1; a=rsa-sha256; c=relaxed/relaxed; d=yahoo.fr; s=s2048; t=1613222867; bh=cx/dmoNLfE1K3fbrrMyYvQr3sPAqiURobU5QR4iT6v4=; h=Date:From:To:In-Reply-To:References:Subject:From:Subject:Reply-To; b=AZfxvi6oYjs6GRFwj3mho+/ALA0F8Ik02Q6BhUQvRd0CExEk7fkOPyPkLCp1Aaia3xhxsHf2zQfBKR63pMlJM+V2OjGPP0w8SkQnDeBvmmuGJtkCg+3B4K2CH6E9W9Vf3QLTgvq18tESf0PGu+8SLcmrro+uG58lQCc1vRi00gjFYnlwbGDNAiaPO50XtvIMZKiCJZ0VAC9UvCywYu7Phn1JohcaKItDXhtJS9WZhVy8qe5urDmuvNigGCoZfOPcBmyGYPCX2sfVSpxHM66UdZ8Aj+/Tm6uzvChtR6eSYfEwYjeNYqLpKjZMlA4Rye4xj4gQTFhnxphIwW1yZcrYAw==
X-SONIC-DKIM-SIGN: v=1; a=rsa-sha256; c=relaxed/relaxed; d=yahoo.com; s=s2048; t=1613222867; bh=4oxIMbo9k+/trHL2dfkS6RDpXAkx2GeffcwMtpJax/b=; h=X-Sonic-MF:Date:From:To:Subject:From:Subject; b=b3r6aDx+ifWFXLXAI49SFqVt04ep85McWmz4AwcVD4WX63gpZrg4Vx1jla7Zbv8M/XzUIPyOshGjgSzHwfqNxGo4rBo2bbrA9sSw6HcrPrzONZ8sczWLzEVf1k5ehu2sMdmnEtmstAlbOkHFMgUXfy6fBai5uqPE+S7lxbUIsCDALolxcFFcPppWFs4YpS2wXJcn7lLTk5/y6tKSNRV4eyw+66tVrSj56zN2BebioDtZl1mZzpYK7P0s5zyfkTUHOk6KcADzpm5PgYu03dzqSxBvJ60PbslFHp4twtJ7dVIspjJaFT8xCY5Ty5tBH5KCcQ0suKzj7hrdCevznJvLGQ==
X-YMail-OSG: 6fBJiyQVM1l6_w52GV9FxDZ5BFMJ4SFYP5YeE24GF5UcMlz_e8VipLKnpIQiDeW
 zGAUZq8bDptJ6NYudoPXN0USrMVNtlGbS2MCGrrzaNpn79B92mRMwxdJjVlvjhqT5Uq6hLnIFYpZ
 .sIC.c4RpQrx_SYs_4O5efRLC_n9oO3nhp3qdZBzBUfVdTEYeeBDKNpP7yvqqB77fssD71OkYL0I
 Lp6MRbYyhkOe4oMW_E0G36mkV1p9fJh.86xp0TwcddnB8YqZ_.YuxNV20gDGkHKKhqO9sp3Yc_Fu
 11ye7xgd6LsLxoOQAmvqpOVPSdN1kcecuRKtlCYqfwLTd_SC_f3JoCCItejlIjj7o2I7sWIbzhQF
 2yIKFfwTOI7RG_K27IZYKaH7TrPeX7dlY0U_J8xr56WIyf0sqKMSvQKJy2mlDlnJ4TV01mleTErI
 u2HO2FfinJLR7jtP3Z19nzRZy3FcPsAzy2Z6V4.1QPVtcjC2wr6UItwncNFuqNRxWD_rdgXws4Yu
 Ar501PPejkbIOrdSBHHQRTiMk0Q7VRfRTRVvqjUh.blaj_4iQE.umsjtLApyL2f9a0xIIP_lyT.1
 8fdEwO5uwPy5QAAfbKm6cpvGxsLfJKXoD_Ouqu9G8PIWy5otdvVbgHW2NqK0V3kBfsDckkQkMZ6p
 Tlm76ED6kN2LlHhuMQT14ceasd7MMxBKWCBrgGkb1NQ4KM7Kk1ycHZ970WKnchMB1pXmgxBq.pX1
 VbzcU6gLE3oNyifQZYeggvtxVYgduJQM.PakR.QVozssLYlzXLTZh4hzbLsgNOgBwVZ5wfm3E2D6
 KLiSDZsH6DyWAOC7e_DT.B_tF5zOUqXamrbt1ZcLaRMdAgmyjJdIddiA_jo3LFewSuEwZt48clzc
 PjL4qNBYXJTavJudSSqheygjmiDrvQinRw3KacIlz3bqBYG0WMMo8R7mcaf3pzHlAEmgWa54ymLl
 3PtU7l_LuADbUV9UV0CbH_8qn1aOoMgEtqUTSaYQZJncyKoCwcbEy6bsdFnqKeTERTI0Heulm78x
 d_ToBVWa0Dv0qIPzcQzveFnS8Wh_ZfRyRxPqTK6zkXrKm5OXGPEc.KCvPW2KKUm1eAOhJfEUFuIB
 N3PITEtM7u8ILkGzceNHtlV5ZMDH_m7ebG5d6SCkA6RNOEi3VK.QY35TseE6A6EjzwLYqBAgDLDI
 XQShQ6Gksh9u.XVGmL9HIUVp0yYQ61Zdc1XNszqPquecSCOVw61d2Ub5wCJp.sCyEbCb_nCbgkgd
 83yHcDuG2RRC.Gvb4Vj_N1bEJ5Ifvlb6OGmraZBgXoDByfNP4xYudU3xTxTC4e6gsMbJRrQQR63G
 59ifznj28TILxI9unhkjqKoet9iud0PVBeOc9C8irplMygq92Vl41dICLjGr0vWF7FJGGgbA51_h
 F3F_FTNJXqjLz4xiIJZlOhKdu6gknnw8rJset9OrcYmlNgTQXsSohmz7JAlwL3lK.NFH6KXyhdlY
 pTsjOCvffVbinAR87uv9N5yBkVAZi8Pgt.5ASZ0TKeyho4n2uYS.yRuFToMzYih2MjqYBq6fJ8Wy
 _vRIiR6LrTA.nIDVeQZDwb1XsXTqycSEpoL9ruDpNTaK8r58FcU6njxfAFvPdNL0g1VkPl9r6apm
 y3Yuv39yJ4MnvuaFvpfSl2V4qaB7NmoHDFI985.mrazvPjrMJK4jaEUZpzt5Y2nJ_5jVzk0.a1DU
 5HN8QCgTqYKH4YrZSZDg13ptO.9VzJmv1jtgo755_uQ21EsWh9D.NMe8UVe5KACqmAMH5VW5DOLD
 YuDPck1aAGWrQOHgytSF9soRnKiQnDOQfanlcVfHKcUYw1P69GqAOtP.yt09MfnRUSI20eAEZx_k
 Rv7jRmmP2EniSyJDiqsmu9k0nIHS4PaFRVHwr6e4JOQSzylP1z4ArZtk3TVsK.P10DqZP8egGXm9
 MGANhNXcxUEpl5G0kl3osSstGSmHC0l1tZXghnEV_.MNrDEcA0jNivi63Vj2E2TLz2QF6o5cDeRO
 zgHVFQW_Mv6tVCM3dRLvB_ql2USUTNCMl2vPUvJ3Pt4SVXYh9zXdWB77xDX7zDRYT.m30c4_acY2
 _D6HcJeM3_H0Rx7k3V.doZo2Ryk1Zep4Io6vV.mqlqm8B7b0LMGuIm1HGyY5HH0cnxObsMLh7Cm5
 Q0wsC.lZh9SYkDTZsbpIQYYlkTqr38dJwXGVhNnoVaF0QomiA..bayAfMwNWHAHOqPBZ8V0kcwYH
 bh6qTdYGXM7YC3q5H7yoOJOjQ2vWQZJ7D3Uhg1wT4ZBy1F.vj8Xvll_Bw_X_9_lSK9RqLCMuGJJ7
 Ihe7777p1H8R8n_0RflS2x7q2Fl2sMYsO9FcGFb4NcLS1YfY2o9gilIAKTeSHn48VcAdxAyx.UwO
 KQFI8ffJIj7l.xcs4Jv9gvko2HN5RbVVqQLO1SesgQvdKDqRbd7sZGgKeKsc2nN8GEKK0BW79rOF
 Lc.iowi0T90nc_U0erbNL22v4dWdm3o5GmYVM8tz8m9tgizwx1yAPvfyps517AImcH7XYgla41I.
 Qxn0boGlR3vZZqxfzO_OQa3MqGzWfgv0c974C1hPzDt062HyfLDpY7Q7j54OUzes9JJLh5Pjw_Ym
 UGWlOa2_K91BL0mo3T6FOVxYKT3Zv
X-Sonic-MF: <hajer_bz@yahoo.fr>
Received: from sonic.gate.mail.ne1.yahoo.com by sonic301.consmr.mail.bf2.yahoo.com with HTTP; Sat, 13 Feb 2021 13:27:47 +0000
Date: Sat, 13 Feb 2021 13:27:41 +0000 (UTC)
From: "Hajer Baazaoui Ep. Zghal" <hajer_bz@yahoo.fr>
To: Liste-egc <liste-egc@polytech.univ-nantes.fr>, 
	"bulle-i3@irit.fr" <bulle-i3@irit.fr>, Info-ic <info-ic@inria.fr>, 
	Bull-ia <bull-ia@gdria.fr>
Message-ID: <216210724.1115064.1613222861614@mail.yahoo.com>
In-Reply-To: <1000557243.90928.1612952801122@mail.yahoo.com>
References: <1000557243.90928.1612952801122.ref@mail.yahoo.com> <1000557243.90928.1612952801122@mail.yahoo.com>
MIME-Version: 1.0
Content-Type: multipart/alternative; 
	boundary="----=_Part_1115063_104396410.1613222861612"
X-Mailer: WebService/1.1.17712 YMailNorrin Mozilla/5.0 (Windows NT 10.0; Win64; x64) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/88.0.4324.150 Safari/537.36
X-Validation-by: p_bruneau@hotmail.com
Subject: [liste-egc] Offre de stage: =?UTF-8?Q?Int=C3=A9gration?= de
 =?UTF-8?Q?donn=C3=A9es?= pharmaceutiques =?UTF-8?Q?bas=C3=A9e?=
 sur les ontologies

------=_Part_1115063_104396410.1613222861612
Content-Type: text/plain; charset=UTF-8
Content-Transfer-Encoding: quoted-printable

Bonjour =C3=A0 tous,



Ci-apr=C3=A8s une offre de stage.=C2=A0

Description du stage :

--------------------------=C2=A0

La tra=C3=A7abilit=C3=A9des m=C3=A9dicaments est actuellement un domaine tr=
=C3=A8s difficile compte tenu de lacomplexit=C3=A9 des probl=C3=A8mes =C3=
=A9conomiques, vieillissement de la population, =E2=80=A6Si cesprobl=C3=A8m=
es sont r=C3=A9solus de mani=C3=A8re ad=C3=A9quate, ils peuvent conduire =
=C3=A0 desam=C3=A9liorations significatives pour toutes les parties prenant=
es, y compris lesorganisations de sant=C3=A9, les utilisateurs finaux et l'=
industrie pharmaceutique.=20

L'objectif duprojet dans le cadre duquel est propos=C3=A9 ce stage, est d'=
=C3=A9tudier et de d=C3=A9finirun nouveau mod=C3=A8le de tra=C3=A7abilit=C3=
=A9 pharmaceutique, qui am=C3=A9liorerait la protectionutilisateurs. Cette =
probl=C3=A9matique n=C3=A9cessite des comp=C3=A9tences multiples etcompl=C3=
=A9mentaires dans les domaines de la s=C3=A9mantique, de la gestion desconn=
aissances, des approches d'optimisation multi-objectif, des technologiesblo=
ckchain, et des comp=C3=A9tences =C3=A9conomiques, =C3=A9galement chercheur=
 pharmaceutiqueainsi que des industriels.

L=E2=80=99objectif du pr=C3=A9sent stage est de proposer une approched=E2=
=80=99int=C3=A9gration de donn=C3=A9es bas=C3=A9e sur les ontologies. Il s=
=E2=80=99agit de pr=C3=A9parer l=E2=80=99int=C3=A9grationvirtuelle des donn=
=C3=A9es =C3=A0 partir de leurs sources bas=C3=A9es sur la s=C3=A9mantique,=
d=E2=80=99identifier et d=E2=80=99int=C3=A9grer des donn=C3=A9es pharmaceut=
iques pour mettre en =C5=93uvrecette approche. L=E2=80=99approches=C3=A9man=
tique d'int=C3=A9gration virtuelle des donn=C3=A9es permettra de fournir un=
e vueint=C3=A9gr=C3=A9e et li=C3=A9e des donn=C3=A9es. Il s=E2=80=99agit au=
ssi de faire un mapping entrel'ontologie et les m=C3=A9tadonn=C3=A9es, ensu=
ite cr=C3=A9er un graphe de connaissances quirelie s=C3=A9mantiquement ces =
mappings afin d=E2=80=99identifier des relations pluscomplexes entre les do=
nn=C3=A9es.=20

Un prototype devrait =C3=AAtre implant=C3=A9 et aussiexp=C3=A9riment=C3=A9.

=C2=A0

- Pour postuler, envoyer une lettre demotivation et un CV =C3=A0 l=E2=80=99=
adresse suivante:=C2=A0musemedproject.inex2020@gmail.com=20

- Dur=C3=A9e et gratification : 6 mois =C3=A0 partirde d=C3=A9but mars 2021=
=C2=A0(selon profil).=C2=A0La gratification vers=C3=A9e correspondau montan=
t l=C3=A9gal

- Lieu : laboratoire ETIS =E2=80=93 CY ParisUniversit=C3=A9 - France

- Financement : MuseMed Project (CYInitiative)

- Profil : formation Bac + 5 eninformatique=C2=A0(ing=C3=A9nieur ou M2)

- Possibilit=C3=A9 de continuer en th=C3=A8se dedoctorat

- Comp=C3=A9tences techniques et pr=C3=A9-requis:=C2=A0

- ma=C3=AEtrisedes langages de programmation: Java & Python;

-il est serait souhaitable d=E2=80=99avoir des connaissances et une exp=C3=
=A9rience avec les technologies du web s=C3=A9mantique (RDF, OWL, SPARQL,=
=E2=80=A6)et les graphes de connaissances

=C2=A0- Langues : Un bon niveau en fran=C3=A7ais eten anglais.=C2=A0
=C2=A0
Cordialement

Prof. Hajer Baazaoui

Responsable du projet MuseMed

 =20
------=_Part_1115063_104396410.1613222861612
Content-Type: text/html; charset=UTF-8
Content-Transfer-Encoding: quoted-printable

<html><head></head><body><div class=3D"ydpfbc14855yahoo-style-wrap" style=
=3D"font-family: times new roman, new york, times, serif; font-size: 16px;"=
><div><div dir=3D"ltr" data-setdir=3D"false"><span style=3D"color: rgb(38, =
40, 42); font-family: Garamond, serif; font-size: 12pt; text-align: justify=
;">Bonjour =C3=A0 tous,</span><br></div></div></div><div id=3D"ydp113e9201y=
ahoo_quoted_4138868934" class=3D"ydp113e9201yahoo_quoted"><div style=3D"fon=
t-family:'Helvetica Neue', Helvetica, Arial, sans-serif;font-size:13px;colo=
r:#26282a;"><div><div id=3D"ydp113e9201yiv2286835477"><div class=3D"ydp113e=
9201yiv2286835477ydp641ea65fyahoo-style-wrap" style=3D"font-family:times ne=
w roman, new york, times, serif;font-size:16px;" dir=3D"ltr"><div><p class=
=3D"ydp113e9201yiv2286835477ydpceab8493MsoNormal" style=3D"margin-bottom:0c=
m;margin-bottom:.0001pt;text-align:justify;line-height:normal;"><span style=
=3D"font-size:12.0pt;font-family:Garamond, serif;"></span></p>

<p class=3D"ydp113e9201yiv2286835477ydpceab8493MsoNormal" style=3D"margin-b=
ottom:0cm;margin-bottom:.0001pt;text-align:justify;line-height:normal;"><sp=
an style=3D"font-size:12.0pt;font-family:Garamond, serif;color:#26282A;">Ci=
-apr=C3=A8s une offre de stage.</span><span style=3D"color:rgb(38, 40, 42);=
font-family:Garamond, serif;font-size:12pt;">&nbsp;</span></p>

<p class=3D"ydp113e9201yiv2286835477ydpceab8493MsoNormal" style=3D"margin-b=
ottom:0cm;margin-bottom:.0001pt;text-align:justify;line-height:normal;"><sp=
an style=3D"font-size:12.0pt;font-family:Garamond, serif;color:#26282A;">De=
scription du stage :</span></p>

<p class=3D"ydp113e9201yiv2286835477ydpceab8493MsoNormal" style=3D"margin-b=
ottom:0cm;margin-bottom:.0001pt;text-align:justify;line-height:normal;"><sp=
an style=3D"font-size:12.0pt;font-family:Garamond, serif;color:#26282A;">--=
------------------------&nbsp;</span></p>

<p class=3D"ydp113e9201yiv2286835477ydpceab8493MsoNormal" style=3D"text-ali=
gn:justify;"><span style=3D"font-size:12.0pt;line-height:107%;font-family:G=
aramond, serif;">La tra=C3=A7abilit=C3=A9
des m=C3=A9dicaments est actuellement un domaine tr=C3=A8s difficile compte=
 tenu de la
complexit=C3=A9 des probl=C3=A8mes =C3=A9conomiques, vieillissement de la p=
opulation, =E2=80=A6Si ces
probl=C3=A8mes sont r=C3=A9solus de mani=C3=A8re ad=C3=A9quate, ils peuvent=
 conduire =C3=A0 des
am=C3=A9liorations significatives pour toutes les parties prenantes, y comp=
ris les
organisations de sant=C3=A9, les utilisateurs finaux et l'industrie pharmac=
eutique. </span></p>

<p class=3D"ydp113e9201yiv2286835477ydpceab8493MsoNormal" style=3D"text-ali=
gn:justify;"><span style=3D"font-size:12.0pt;line-height:107%;font-family:G=
aramond, serif;">L'objectif du
projet dans le cadre duquel est propos=C3=A9 ce stage, est d'=C3=A9tudier e=
t de d=C3=A9finir
un nouveau mod=C3=A8le de tra=C3=A7abilit=C3=A9 pharmaceutique, qui am=C3=
=A9liorerait la protection
utilisateurs. Cette probl=C3=A9matique n=C3=A9cessite des comp=C3=A9tences =
multiples et
compl=C3=A9mentaires dans les domaines de la s=C3=A9mantique, de la gestion=
 des
connaissances, des approches d'optimisation multi-objectif, des technologie=
s
blockchain, et des comp=C3=A9tences =C3=A9conomiques, =C3=A9galement cherch=
eur pharmaceutique
ainsi que des industriels.</span><span style=3D"font-size:12.0pt;line-heigh=
t:107%;font-family:Garamond, serif;"></span></p>

<p class=3D"ydp113e9201yiv2286835477ydpceab8493MsoNormal" style=3D"margin-b=
ottom:0cm;margin-bottom:.0001pt;text-align:justify;line-height:normal;"><sp=
an style=3D"font-size:12.0pt;font-family:Garamond, serif;color:#26282A;">L=
=E2=80=99objectif du pr=C3=A9sent stage est de </span><span lang=3D"EN-GB" =
style=3D"font-size:12.0pt;font-family:Garamond, serif;color:#26282A;">propo=
ser une approche
d=E2=80=99int=C3=A9gration de donn=C3=A9es bas=C3=A9e sur les ontologies. I=
l s=E2=80=99agit de pr=C3=A9parer l=E2=80=99int=C3=A9gration
virtuelle des donn=C3=A9es =C3=A0 partir de leurs sources bas=C3=A9es sur l=
a s=C3=A9mantique,
d=E2=80=99identifier et d=E2=80=99int=C3=A9grer des donn=C3=A9es pharmaceut=
iques pour mettre en =C5=93uvre
cette approche. L=E2=80=99</span><span style=3D"font-size:12.0pt;font-famil=
y:Garamond, serif;">approche
s=C3=A9mantique d'int=C3=A9gration virtuelle des donn=C3=A9es permettra de =
fournir une vue
int=C3=A9gr=C3=A9e et li=C3=A9e des donn=C3=A9es. Il s=E2=80=99agit aussi d=
e faire un mapping entre
l'ontologie et les m=C3=A9tadonn=C3=A9es, ensuite cr=C3=A9er un graphe de c=
onnaissances qui
relie s=C3=A9mantiquement ces mappings afin d=E2=80=99identifier des relati=
ons plus
complexes entre les donn=C3=A9es. </span></p>

<p class=3D"ydp113e9201yiv2286835477ydpceab8493MsoNormal" style=3D"margin-b=
ottom:0cm;margin-bottom:.0001pt;text-align:justify;line-height:normal;"><sp=
an lang=3D"EN-GB" style=3D"font-size:12.0pt;font-family:Garamond, serif;col=
or:#26282A;">Un prototype devrait =C3=AAtre implant=C3=A9 et aussi
exp=C3=A9riment=C3=A9.</span></p>

<p class=3D"ydp113e9201yiv2286835477ydpceab8493MsoNormal" style=3D"margin-b=
ottom:0cm;margin-bottom:.0001pt;text-align:justify;line-height:normal;"><sp=
an style=3D"font-size:12.0pt;font-family:Garamond, serif;color:#26282A;">&n=
bsp;</span></p>

<p class=3D"ydp113e9201yiv2286835477ydpceab8493MsoNormal" style=3D"margin-b=
ottom:0cm;margin-bottom:.0001pt;text-align:justify;line-height:normal;"><sp=
an style=3D"font-size:12.0pt;font-family:Garamond, serif;color:#26282A;">- =
Pour postuler, envoyer une lettre de
motivation et un CV =C3=A0 l=E2=80=99adresse suivante:&nbsp;</span><a href=
=3D"mailto:musemedproject.inex2020@gmail.com" rel=3D"nofollow" target=3D"_b=
lank"><b><span style=3D"font-size:12.0pt;font-family:Garamond, serif;">muse=
medproject.inex2020@gmail.com</span></b></a><b><span style=3D"font-size:12.=
0pt;font-family:Garamond, serif;color:#26282A;"> </span></b></p>

<p class=3D"ydp113e9201yiv2286835477ydpceab8493MsoNormal" style=3D"margin-b=
ottom:0cm;margin-bottom:.0001pt;text-align:justify;line-height:normal;"><sp=
an style=3D"font-size:12.0pt;font-family:Garamond, serif;color:black;">- Du=
r=C3=A9e et gratification : 6 mois =C3=A0 partir
de d=C3=A9but mars 2021&nbsp;(selon profil).&nbsp;La gratification vers=C3=
=A9e correspond
au montant l=C3=A9gal</span></p>

<p class=3D"ydp113e9201yiv2286835477ydpceab8493MsoNormal" style=3D"margin-b=
ottom:0cm;margin-bottom:.0001pt;text-align:justify;line-height:normal;"><sp=
an style=3D"font-size:12.0pt;font-family:Garamond, serif;color:black;">- Li=
eu : laboratoire ETIS =E2=80=93 CY Paris
Universit=C3=A9 - France</span></p>

<p class=3D"ydp113e9201yiv2286835477ydpceab8493MsoNormal" style=3D"margin-b=
ottom:0cm;margin-bottom:.0001pt;text-align:justify;line-height:normal;"><sp=
an style=3D"font-size:12.0pt;font-family:Garamond, serif;color:black;">- Fi=
nancement : MuseMed Project (CY
Initiative)</span></p>

<p class=3D"ydp113e9201yiv2286835477ydpceab8493MsoNormal" style=3D"margin-b=
ottom:0cm;margin-bottom:.0001pt;text-align:justify;line-height:normal;"><sp=
an style=3D"font-size:12.0pt;font-family:Garamond, serif;color:black;">- Pr=
ofil : formation Bac + 5 en
informatique&nbsp;(ing=C3=A9nieur ou M2)</span></p>

<p class=3D"ydp113e9201yiv2286835477ydpceab8493MsoNormal" style=3D"margin-b=
ottom:0cm;margin-bottom:.0001pt;text-align:justify;line-height:normal;"><sp=
an style=3D"font-size:12.0pt;font-family:Garamond, serif;color:black;">- Po=
ssibilit=C3=A9 de continuer en th=C3=A8se de
doctorat</span></p>

<p class=3D"ydp113e9201yiv2286835477ydpceab8493MsoNormal" style=3D"margin-b=
ottom:0cm;margin-bottom:.0001pt;text-align:justify;line-height:normal;"><sp=
an style=3D"font-size:12.0pt;font-family:Garamond, serif;color:black;">- Co=
mp=C3=A9tences techniques et pr=C3=A9-requis:&nbsp;
</span></p>

<p class=3D"ydp113e9201yiv2286835477ydpceab8493MsoNormal" style=3D"margin-b=
ottom:0cm;margin-bottom:.0001pt;text-align:justify;text-indent:18.0pt;line-=
height:normal;"><span style=3D"font-size:12.0pt;font-family:Garamond, serif=
;color:black;">- ma=C3=AEtrise
des langages de programmation: Java &amp; Python;</span></p>

<p class=3D"ydp113e9201yiv2286835477ydpceab8493MsoNormal" style=3D"margin-b=
ottom:0cm;margin-bottom:.0001pt;text-align:justify;text-indent:18.0pt;line-=
height:normal;"><span style=3D"font-size:12.0pt;font-family:Garamond, serif=
;color:black;">-
il est serait souhaitable d=E2=80=99avoir des connaissances et une exp=C3=
=A9rience avec les technologies du web s=C3=A9mantique (RDF, OWL, SPARQL,=
=E2=80=A6)
et les graphes de connaissances</span></p>

<p class=3D"ydp113e9201yiv2286835477ydpceab8493MsoNormal" style=3D"margin-b=
ottom:0cm;margin-bottom:.0001pt;text-align:justify;line-height:normal;"><sp=
an style=3D"font-size:12.0pt;font-family:Garamond, serif;color:black;">&nbs=
p;</span><span style=3D"font-family:Garamond, serif;font-size:12pt;">- Lang=
ues : Un bon niveau en fran=C3=A7ais et
en anglais.&nbsp;</span></p>

<div style=3D"text-align:justify;"><span style=3D"font-size:12.0pt;line-hei=
ght:107%;font-family:Garamond, serif;">&nbsp;</span></div><div style=3D"tex=
t-align:justify;" dir=3D"ltr"><div><div><br></div><div><span style=3D"color=
:rgb(38, 40, 42);font-family:Garamond, serif;font-size:16px;text-align:just=
ify;">Cordialement</span><br></div></div></div>

<p class=3D"ydp113e9201yiv2286835477ydpceab8493MsoNormal" style=3D"text-ali=
gn:justify;"><span style=3D"font-size:12.0pt;line-height:107%;font-family:G=
aramond, serif;">Prof. Hajer Baazaoui</span></p>

<p class=3D"ydp113e9201yiv2286835477ydpceab8493MsoNormal" style=3D"text-ali=
gn:justify;"><span style=3D"font-size:12.0pt;line-height:107%;font-family:G=
aramond, serif;">Responsable du projet </span><span style=3D"font-size:12.0=
pt;line-height:107%;font-family:Garamond, serif;color:black;">MuseMed</span=
><span style=3D"font-size:12.0pt;line-height:107%;font-family:Garamond, ser=
if;"></span></p></div></div></div><br></div>
            </div>
        </div></body></html>
------=_Part_1115063_104396410.1613222861612--
